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The 3 mammalian Orais are tetraspanin-like proteins of Ca2+-permeable plasma membrane channels.1 The most 
studied is Orai1, a key player in the Ca2+ release–activated 
Ca2+ (CRAC) channels of T cells.1 An activator of Orai1 is 
the stromal interaction molecule 1 (STIM1), which con-
fers a link between Ca2+ from the endoplasmic reticulum 
and Orai1-dependent channels at the plasma membrane.2 
The related Orai3 is also capable of generating CRAC 
channel-like currents when overexpressed in cell lines, as is 
native Orai3 in estrogen receptor positive breast cancer cell 
lines.3,4 However, endogenous Orai3 does not contribute to 
store depletion-evoked Ca2+ entry in vascular cell types.5,6 
Intriguing studies suggest that Orai3 importantly contrib-
utes to separate but related Ca2+ entry channels operating 
independently of store depletion: arachidonic acid (AA)–
regulated Ca2+ channels.7 Such channels exist in cell lines, 
primary acinar cells, vascular smooth muscle cells and 
taste bud cells7–9 and arise from heteromers of Orai1 and 
Orai3.10,11 Studies in HEK 293 cells suggest plasma mem-
brane STIM1 is essential for AA–regulated Ca2+ channel 
activation.12–14 In HEK 293 cells, AA acts as an activator 
depending on the N-terminus of Orai3.15 Studies of vascu-
lar smooth muscle cells suggest the contribution of Orai3 
to leukotriene C4 (LTC4) regulated Ca2+ channels.16–18 These 
channels rely on an interaction with endoplasmic reticulum–
resident STIM117,18 and are activated by the AA metabolite 
LTC4 generated through the 5-lipoxygenase pathway by 
LTC4 synthase (LTC4S).19
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Objective––Vascular endothelial growth factor (VEGF) acts, in part, by triggering calcium ion (Ca2+) entry. Here, we sought 
understanding of a Synta66-resistant Ca2+ entry pathway activated by VEGF..
Approach and Results––Measurement of intracellular Ca2+ in human umbilical vein endothelial cells detected a Synta66-
resistant component of VEGF-activated Ca2+ entry that occurred within 2 minutes after VEGF exposure. Knockdown 
of the channel-forming protein Orai3 suppressed this Ca2+ entry. Similar effects occurred in 3 further types of human 
endothelial cell. Orai3 knockdown was inhibitory for VEGF-dependent endothelial tube formation in Matrigel in vitro 
and in vivo in the mouse. Unexpectedly, immunofluorescence and biotinylation experiments showed that Orai3 was 
not at the surface membrane unless VEGF was applied, after which it accumulated in the membrane within 2 minutes. 
The signaling pathway coupling VEGF to the effect on Orai3 involved activation of phospholipase Cγ1, Ca2+ release, 
cytosolic group IV phospholipase A2α, arachidonic acid production, and, in part, microsomal glutathione S-transferase 
2, an enzyme which catalyses the formation of leukotriene C4 from arachidonic acid. Shear stress reduced microsomal 
glutathione S-transferase 2 expression while inducing expression of leukotriene C4 synthase, suggesting reciprocal 
regulation of leukotriene C4–synthesizing enzymes and greater role of microsomal glutathione S-transferase 2 in low 
shear stress.
Conclusions––VEGF signaling via arachidonic acid and arachidonic acid metabolism causes Orai3 to accumulate at the cell 
surface to mediate Ca2+ entry and downstream endothelial cell remodeling.  (Arterioscler Thromb Vasc Biol. 2015;35: 
1987-1994. DOI: 10.1161/ATVBAHA.115.305969.)
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Vascular endothelial growth factor (VEGF) is a primary 
inducer of endothelial cell function, for example in the regula-
tion of vascular permeability and angiogenesis.20 Intracellular 
Ca2+ elevation is an early event in the action of VEGF acting 
through VEGF receptor-2 (VEGFR2).21,22 It arises because of 
Ca2+ release from intracellular stores and multiple types of 
Ca2+ entry that sustain the cytosolic Ca2+ elevation.23,24 One 
type of Ca2+ entry occurs through endogenous CRAC-like 
channels because it is partially suppressed by knockdown of 
Orai1 or STIM1 and by a small molecule inhibitor of CRAC 
channels, Synta66 (S66).22 S66 has been studied for effects on 
>50 ion channels, receptors, transporters, and calcium release 
mechanisms and no significant effects were observed; it seems 
to be a specific inhibitor of CRAC channels.6,22,25,26 However, 
there is also an Orai1/STIM1-dependent signal that is resistant 
to CRAC channel blockade.22 Therefore, Orai1 and STIM1 
contribute not only to a CRAC channel but also to a pharma-
cologically distinct S66-resistant Ca2+ entry channel. Here, we 
investigated the role of Orai3 and the activation mechanism 
for these S66-resistant channels.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Orai3 Mediates VEGF-Evoked Ca2+ Entry  
in HUVECs
In the absence of extracellular Ca2+, VEGF (30 ng/mL) caused 
a Ca2+ release event, which reached a maximum in 3 minutes 
and then decayed (Figure 1A). In the presence of physiologi-
cal Ca2+, VEGF caused greater elevation of intracellular Ca2+, 
which reached a maximum in 2 minutes (Figure 1A). CRAC 
channel inhibition by S66 had no effect on the rising phase 
of this Ca2+ elevation but suppressed the later sustained phase 
(Figure 1B). To investigate the role of Orai3, we performed 
siRNA-mediated knockdown using 2 different siRNAs that 
reduced the abundance of Orai3 without affecting expression 
of Orai1, Orai2, STIM1, or STIM2 or the STIM1-regulated 
Nonstandard Abbreviations and Acronyms
AA arachidonic acid
cPLA2α cytosolic group IV phospholipase A2α
CRAC Ca2+ release–activated Ca2+
HEK human embryonic kidney
HUVEC human umbilical vein endothelial cells
LTC4 leukotriene C4
LTC4S LTC4 synthase
MGST2 microsomal glutathione S-transferase 2
STIM1 stromal interaction molecule 1
VEGF vascular endothelial growth factor
Figure 1. Role of Orai3 in vascular endothelial growth factor (VEGF)–evoked Ca2+ entry and endothelial cell remodeling. A, Example 
responses to VEGF stimulation (30 ng/mL) from human umbilical vein endothelial cells (HUVECs) in the presence or absence of Ca2+ (n=4/
N=16). B, Example VEGF responses from HUVECs in the presence of Synta66 (S66; (5 μmol/L) or vehicle control (n=3/N=32 each). C, 
Example responses to VEGF stimulation (30 ng/mL) from HUVECs treated with scrambled (scr.) or Orai3_1 (O3_1) siRNA (n=3/N=60) each. 
D, Mean VEGF responses from HUVECs at peak or sustained (330 s) for cells transfected with scrambled (scr.), Orai3_1 (O3_1) or Orai3_2 
(O3_2) siRNA (n=3/N=32 each). E, As for (C) but in the absence of extracellular Ca2+ (n=3/N=64 each). F, Example responses to VEGF 
stimulation (30 ng/mL) from cardiac microvascular endothelial cells (CMECs ; n=3/N=48 each), saphenous vein endothelial cells (SVECs; 
n=3/N=24 each), and liver endothelial cells (LECs; n=5/N=25 each). G, Mean data and analysis of data from CMECs (CM.), SVECs (SV.), 
and LECs as exemplified in (F). H, In vitro tube lengths of HUVECs after transfection with scr. or O3_1 siRNA; or scr. compared with O3_1 
plus wild-type (WT) Orai3 clone (n=3 each). Scale bar, 50 μm. I, In vivo tube length of HUVECs in mice after transfection with scr. or O3_1 
siRNA (5 independent experiments: i–v). Scale bars, 50 μm. Data are represented as mean±SEM. *P<0.05; not significant (ns) P>0.05.
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TRPC1, TRPC4, or TRPC5 channels (Figure IA–IE in the 
online-only Data Supplement). Knockdown of Orai3 reduced 
the VEGF-evoked Ca2+ entry by 69% to 72% at its peak 
and 7% to 18% at the sustained phase measured at 330 s 
(Figure 1C and 1D). Ca2+ release was unaffected (Figure 1E). 
The data suggest importance of Orai3 in the early phase of 
VEGF-evoked Ca2+ entry.
Orai3 Mediates VEGF-Evoked Ca2+ Entry in 
a Variety of Human Endothelial Cell Types
To address the relevance to other endothelial cells, we first 
studied human cardiac microvascular endothelial cells. There 
was robust Orai3-dependent Ca2+ elevation in response to 
VEGF, similar to that in human umbilical vein endothelial 
cells (HUVECs; Figure 1F and 1G). To determine the rele-
vance to patients, we isolated endothelial cells from saphe-
nous vein obtained at coronary artery bypass grafting. Again 
a similar Orai3-dependent VEGF response was observed 
(Figure 1F and 1G). We also isolated sinusoidal endothelial 
cells from normal liver tissue obtained at resection for colorec-
tal liver metastases: the VEGF response was similar to that of 
HUVECs and had similar Orai3-dependence (Figure 1F and 
1G). The data suggest that Orai3 is a significant contributor to 
VEGF signaling in several important vascular settings: mac-
rovascular as well as microvascular, and in patients with coro-
nary artery disease and cancer.
Orai3 Positively Affects VEGF-Induced 
Endothelial Cell Remodeling
To investigate functional consequences of Orai3 in this 
context, we first performed transwell migration and cell 
count assays with HUVECs treated with Orai3 siRNA. 
Orai3 depletion suppressed both migration and proliferation 
(Figure IIA and IIB in the online-only Data Supplement). 
We, therefore, investigated tube formation in coculture 
with fibroblasts and on Matrigel in vitro and in vivo in 
mice. Orai3 siRNA reduced tube length and number of tube 
branches (Figure 1H and 1I; SIIC and IID). Wild-type Orai3 
cDNA rescued tube formation, consistent with Orai3 siRNA 
generating its effect through Orai3 suppression rather than 
an off-target mechanism (Figure 1H). The data suggest 
Orai3 as a positive factor in VEGF-induced endothelial cell 
remodeling.
Exogenous AA Causes Orai3-Dependent Ca2+ Entry
A downstream mechanism of VEGFR2 phosphorylation 
is the activation of PLCγ1 (phospholipase C γ1) leading 
to the production of AA by cytosolic group IV phospho-
lipase A2α (cPLA2α; Figure IIIA in the online-only Data 
Supplement),27–29 which has been previously linked to 
AA–regulated Ca2+ channels.30 The PLC inhibitor U73122 
abolished VEGF-evoked Ca2+ elevation.21,22 Edelfosine, an 
alternative PLC inhibitor, had the same effect (Figure IIIB 
in the online-only Data Supplement). Inhibitors of several 
other signaling elements downstream of VEGFR2 were 
tested and had no effect (Figure IIIB in the online-only 
Data Supplement). Because AA production is downstream 
of PLCγ1, we investigated if it was possible to circumvent 
VEGFR2 by directly applying exogenous AA. The response 
to exogenous AA included Ca2+ release (Figure IIIC and 
IIID) and so we investigated if there was an effect on Ca2+ 
entry independent of release and CRAC channel activation 
Figure 2. Exogenous arachidonic acid (AA) evokes Orai3-dependent Ca2+ entry and microsomal glutathione S-transferase 2 (MGST2) is 
required in the action of vascular endothelial growth factor (VEGF). A, Example responses and mean data of human umbilical vein endothe-
lial cells (HUVECs) exposed to exogenous AA (40 μmol/L). All cells were pretreated with thapsigargin (2 μmol/L) and studied in the presence 
of S66 (5 μmol/L). Cells were transfected with scrambled (scr.) or Orai3 (O3_1) siRNA; (n=3/N=60 each). B, Representative immunoblot of 
MGST2 in HUVECs transfected with scr. or MGST2 siRNA_1 or MGST2 siRNA_2. Untransfected Huh7 cells were used as a positive control 
for MGST2 expression. C, Example VEGF responses and mean data from HUVECs transfected with scr., O3_1 or MGST2_1 siRNA. Mean 
data are for VEGF responses at peak or after 330 s (n=3/N=36 each). Data are represented as mean±SEM; *P<0.05; ns P>0.05.
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by first depleting Ca2+ stores with thapsigargin and includ-
ing S66. Ca2+ was present in the extracellular medium. 
There was robust Ca2+ entry in response to 40 μmol/L AA. 
Lower AA concentrations generated only small inconsistent 
effects (Figure IIIE in the online-only Data Supplement). 
To investigate if 40 μmol/L AA caused nonspecific mem-
brane disruption, we applied 40 μmol/L eicosatetraynoic 
acid, a nonmetabolizeable AA analog, which did not cause 
Ca2+ entry (Figure IIIF in the online-only Data Supplement). 
Moreover, Orai3 siRNA strongly suppressed the AA-evoked 
Ca2+ entry, suggesting that exogenous AA activates the 
Orai3 mechanism without causing membrane disruption 
(Figure 2A). The data are consistent with AA being a com-
ponent of the pathway between VEGF and Orai3 but suggest 
that AA has relatively weak potency in the absence of cofac-
tors triggered by VEGF.
Role of MGST2
We investigated whether AA metabolites are involved in the 
action of VEGF. It was previously suggested that HUVECs 
generate AA metabolites, such as LTC4 by enzymatic activity 
of microsomal glutathione S-transferase 2 (MGST2).31,32 We 
confirmed the expression of MGST2 and knocked down its 
expression by 2 siRNAs (Figure 2B; Figure IIIG in the online-
only Data Supplement). Importantly, there was significant 
reduction in VEGF-evoked Ca2+ entry after MGST2 deple-
tion and the character of the effect of MGST2 depletion was 
similar to that of Orai3 depletion (Figure 2C). Metabolism of 
AA by the cyclooxygenase pathway was not involved because 
indomethacin (10 μmol/L)33 had no effect on VEGF-evoked 
Ca2+ entry (Figure IIIH in the online-only Data Supplement). 
The data suggest a role for AA metabolism by MGST2 in 
VEGF-evoked Orai3-dependent Ca2+ entry.
VEGF Is Required for Orai3 Plasma 
Membrane Localization
For Orai3 to contribute to a Ca2+ entry channel, it has to local-
ize to the plasma membrane. However, we could not detect it 
at the plasma membrane under basal conditions. We, there-
fore, tested if Orai3 was at the plasma membrane after stim-
ulation with VEGF. Cells in the control group were treated 
with sorafenib (1 μmol/L), a multikinase inhibitor, to suppress 
constitutive ligand-independent VEGF receptor signaling. 
Co-staining for CD31 protein defined the location of plasma 
membrane Orai3. Importantly, we could only detect Orai3 at 
the plasma membrane after VEGF stimulation (Figure 3A). To 
further explore the phenomenon, we generated a functional 
Orai3 construct with a hemagglutinin (HA) epitope tag in the 
second extracellular loop (Orai3-[HA]; Figure IVA–IVC in 
the online-only Data Supplement), which allowed detection 
of overexpressed surface-localized Orai3 in nonpermeabi-
lized cells. Again, Orai3 was only at the plasma membrane 
after VEGF stimulation (Figure 3B). Surface accumulation of 
Orai3 in response to VEGF was rapid, occurring within 2 min-
utes after VEGF application (Figure 3B), which aligns well 
with the time course of the Ca2+ elevation (Figure 1A and 1B). 
Figure 3. Selective Orai3 plasma membrane accumulation is evoked by vascular endothelial growth factor (VEGF). A, Representative 
images and mean data of cells treated with sorafenib (1 μmol/L) or vehicle (DMSO [dimethyl sulfoxide]) before stimulation with VEGF (30 
ng/mL) for 5 minutes. Cells were labeled with anti-Orai3 antibody (Orai3, green) and anti-CD31 antibody (CD31, red). Scale bar, 2 μm. 
Arrows point to example cell perimeter as indicated by CD31 labeling. Mean data shows cell-surface Orai3 (n=6/N=18 each). B, Rep-
resentative images and mean data of human umbilical vein endothelial cells (HUVECs) overexpressing Orai3-[HA] and treated as in (A). 
Cells were labeled with the anti-HA antibody. Scale bar, 10 μm. VEGF was applied for 5 minutes (n=3/N=15 each) or 2 minutes (n=3/N=45 
each). C, Representative immunoblot and mean data from 3 experiments for cells treated as in (A) before biotinylation. The arrow points 
to Orai3 labeled by anti-Orai3 antibody (α-Orai3). The protein band above it, labeled nonspecifically by α-Orai3, has unknown identity. 
Where indicated (+), sorafenib (sor.) and VEGF were used at 1 μmol/L and 30 ng/mL, respectively. VEGF was applied for 5 minutes. D, 
Representative images and mean data for mCherry-Orai1 surface localization in cells treated as in (A); (sor., n=7/N=29; VEGF, n=4/N=14). 
Scale bar, 10 μm. All data are from HUVECs. Data are represented as mean±SEM; *P<0.05; ns P>0.05.
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Surface biotinylation experiments confirmed these results 
for endogenous Orai3 (Figure 3C). STIM1 was by contrast 
constitutively at the plasma membrane and not significantly 
increased by VEGF (Figure 3C). Orai1 was likewise at the 
membrane and not affected by VEGF (Figure 3D). The data 
suggest that VEGF triggers Orai3 accumulation at the plasma 
membrane to enable Orai3-dependent Ca2+ entry.
Roles of AA and MGST2 in Membrane 
Accumulation of Orai3
To elucidate a mechanism for the surface accumulation of Orai3, 
we investigated cPLA2α, which generates AA in response to 
VEGF.27–29 Importantly, inhibition of cPLA2α prevented VEGF-
induced plasma membrane accumulation of Orai3 (Figure 4A). 
Furthermore, exogenous AA caused Orai3 surface accu-
mulation (Figure 4B and 4C). Orai1 was not affected by AA 
(Figure 4D). Similarly, STIM1 was constitutively present at the 
plasma membrane and not affected by AA (Figure 4E). In addi-
tion, knockdown of MGST2 reduced VEGF-dependent surface 
localization of Orai3, whereas surface marker proteins, VE cad-
herin and CD71, were unaffected (Figure 4F). The data suggest 
that VEGF evokes surface accumulation of Orai3 via cPLA2α, 
AA and, in part, the metabolism of AA by MGST2.
Reciprocal Regulation of MGST2 and 
LTC4S Gene Expression by Shear Stress
Although endothelial cells exist without shear stress during 
early stages of embryonic and adult angiogenesis and in low 
Figure 4. Selective Orai3 plasma membrane accumulation is evoked by exogenous arachidonic acid (AA) and depends on microsomal 
glutathione S-transferase 2 (MGST2). A, Mean immunofluorescence data for α-Orai3-labeled Orai3 in cells treated with sorafenib (1 
μmol/L), vehicle or cytosolic group IV phospholipase A2α (cPLA2α) inhibitor (1 μmol/L) before stimulation with vascular endothelial growth 
factor (VEGF; 30 ng/mL) for 10 minutes (n=4/N=15 each). B, Representative images and mean data (n=4/N=22 each) of cells treated 
with sorafenib before stimulation with vehicle or AA (40 μmol/L) for 10 minutes. Cells were labeled with anti-Orai3 (green) and anti-CD31 
(red) antibodies. Scale bar, 10 μm. Arrows point to cell perimeter as indicated by signal for CD31. C, Mean data for cells overexpressing 
Orai3-[HA] and treated as in (B; n=3/N=15 each). D, Representative images and mean data for mCherry-Orai1 surface localization in cells 
treated as in (B; vehicle control, n=7/N=29; AA, n=3/N=16 each). Scale bar, 10 μm. E, Representative immunoblot and mean data from 
3 experiments for cell surface Orai3 from cells treated as in (B) before biotinylation. The arrow points to Orai3 labeled by anti-Orai3 anti-
body (α-Orai3). The protein band above it, labeled nonspecifically by α-Orai3, has unknown identity. Where indicated (+), sorafenib and 
AA were used at 1 μmol/L and 40 μmol/L, respectively. AA was applied for 5 minutes. F, Representative immunoblot and mean data from 
3 experiments for cells treated with VEGF (30 ng/mL) for 5 minutes before biotinylation. The arrow points to Orai3 labeled by anti-Orai3 
antibody (α-Orai3). The protein band above it, labeled nonspecifically by α-Orai3, has unknown identity. Where indicated (+), cells were 
transfected with control scrambled (scr.) siRNA or MGST2 siRNA_1. All data are from HUVECs. Data are represented as mean±SEM. 
STIM1 indicates stromal interaction molecule 1. *P<0.05; not significant (ns) P>0.05.
Figure 5. Analysis of MGST2, LTC4S, and Orai3 gene expression in human umbilical vein endothelial cell (HUVEC). A, Example agarose 
gel for end-point polymerase chain reaction products obtained with primers for MGST2, LTC4S, Orai3, and β-actin from HUVEC cDNA. 
Cells were exposed to static and shear-stress conditions, respectively, before harvesting mRNA and reverse transcriptase reaction (+RT 
[reverse transcriptase]) to generate cDNA. −RT denotes control reaction. B, Mean data and analysis of MGST2 and Orai3 mRNA (n=6). 
Data are represented as mean±SEM; *P<0.05.
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or disturbed shear stress in mature vessels, shear stress is a 
force constantly experienced by many endothelial cells and 
a driver for vascular maturation, endothelial cell alignment, 
and other vascular phenomena.34 We, therefore, investigated 
the effect of shear stress on expression of the MGST2 gene. 
Expression of MGST2 was reduced while not abolished by 
shear stress (Figure 5A and 5B). The effect on Orai3 gene 
expression was similar (Figure 5A and 5B). Consistent with 
previous work32 in static conditions, we could not detect 
expression of LTC4S gene, an alternative mechanism for gen-
erating LTC4, but shear stress induced expression of LTC4S 
(Figure 5A). The data suggest a greater role for MGST2 in low 
shear stress conditions and a reciprocal effect of shear stress 
on the expression of MGST2 and LTC4S genes.
Discussion
This study shows relevance of Orai3 to VEGF signaling 
and downstream endothelial cell remodeling. It also shows 
a previously unrecognized mechanism for acute control over 
Ca2+ entry by Orai proteins. The data suggest that Orai3 is 
not constitutively at the plasma membrane but that it rapidly 
accumulates in the membrane in response to VEGF. Induced 
accumulation effectively serves as an activation mechanism. 
Orai1 and STIM1 are not similarly regulated: we find that 
they are constitutively localized to the plasma membrane, 
which is consistent with previous reports.14,18,35 We suggest 
that VEGF-evoked accumulation of Orai3 depends on PLCγ1 
activation, subsequent Ca2+ release that activates cPLA2α, 
catalysis of the production of AA and then metabolism of 
this AA, in part, by MGST2 to generate metabolites, such as 
LTC4. We hypothesize that a combination of AA itself and 
AA metabolites such as LTC4 act on Orai3 to cause its sur-
face accumulation and its activation (if it is not already con-
stitutively active).
It is surprising that Orai3 lacks localization to the plasma 
membrane in endothelial cells under basal conditions. First, it 
contrasts with the situation for Orai1, as shown in this study 
and observed previously.22 Second, overexpression of Orai3 
in the HEK 293 cell line, a commonly used mammalian cell 
expression system, leads to constitutive Orai3 at the plasma 
membrane as shown by previous studies36 and confirmed by 
us (Figure IVD in the online-only Data Supplement). By con-
trast, we found no evidence for similar localization of endog-
enous Orai3 in endothelial cells. There is clearly a technical 
challenge in studying endogenous low abundance membrane 
proteins such as Orai3 and so, while we confirmed the speci-
ficity of our anti-Orai3 antibody for studies of endogenous 
Orai3 in endothelial cells (Figure ID in the online-only Data 
Supplement), it was important to test our hypothesis without 
using this antibody. For this work, we expressed exogenous 
HA-tagged Orai3 in endothelial cells but we were careful to 
use the minimum expression abundance required for detec-
tion, making observations only 6 hours after transfection to 
reduce the likelihood of overexpression and thus artificial bias 
of Orai3 to the plasma membrane.
The reason why there is basal exclusion of Orai3 from 
the surface membrane is unknown but we speculate that it 
is important to avoid incorporation of constitutively active 
Orai3-containing channels that could cause long term, poten-
tially damaging, leak of Ca2+ into the cells. Whatever the 
reason, it presents a mechanistic challenge because, unlike 
Orai3, STIM1, and Orai1 are constitutively at the plasma 
membrane, yet, like Orai3, they both contribute to S66-
resistant Ca2+ entry.22 This raises a question about how Orai3 
integrates with or otherwise influences Orai1 and STIM1. 
We hope to reveal understanding of the mechanisms through 
future studies.
Studies of other cell types have shown dependence of 
Orai3 mechanisms not only on Orai1 and STIM1 but also 
AA and AA metabolism.7,18,37 It is notable that all studies 
have used a relatively high concentration of exogenous AA in 
efforts to mimic the effect of an endogenous receptor agonist. 
To generate a robust response we needed to use 40 μmol/L 
AA. Other studies have used ≤10× less, but such concentra-
tions are still relatively high. This requirement could suggest 
that exogenous AA is inefficient at mimicking AA generated 
enzymatically inside cells or that a cofactor is required to 
activate the mechanism efficiently; activation of VEGFR2 by 
VEGF generates many signaling factors, some of which might 
synergize with AA.
We suggest a Ca2+ release-dependent mechanism for 
activation of this Orai3 system: Ca2+ release activating 
cPLA2α to catalyze the production of AA. This should not 
be taken to mean that Orai3 is activated by store depletion 
in these cells, because it is not (Figure V in the online-only 
Data Supplement). Physiological Ca2+ release does not nec-
essarily cause Ca2+ store depletion. Our previous work on 
growth factor–activated Ca2+ signaling in vascular smooth 
muscle cells35 and measurements of stored Ca2+ in endo-
thelial cells during agonist exposure38 have suggested that 
stores are efficiently maintained replete in the face of Ca2+ 
release because of reuptake of Ca2+ into stores via smooth 
endoplasmic reticulum Ca2+ ATPase. Store depletion is 
a stress to endoplasmic reticulum and so cells will have 
evolved mechanisms to minimize such stress during physi-
ological signaling.
The reciprocal relationship between expression of this 
system and shear stress suggests that it may have greatest 
functional importance at sites with low or disturbed shear 
stress. Such sites occur in embryonic development but also 
at vascular loci in the adult that are vulnerable to disease or 
directly involved in on-going disease. Our detection of this 
Orai3 mechanism in endothelial cells from patients with coro-
nary artery disease and cancer suggests relevance in patho-
physiological settings; in support of this, atherosclerosis, 
tissue injury, cancer, and other related conditions have all been 
associated with increased PLA2 activity and AA.39–42
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Although Ca2+ entry is known to mediate cellular responses to vascular endothelial growth factor (VEGF), there are multiple mechanisms and 
not all of them are defined or understood. Here, we describe a pathway for VEGF-evoked Ca2+ entry that surprisingly requires Orai3-contain-
ing channels. Moreover, it requires rapid accumulation of these channels at the plasma membrane in response to VEGF. Without VEGF, Orai3 
is not at the membrane. Intriguingly, the signaling pathway required for Orai3 accumulation involves the enzyme microsomal glutathione 
S-transferase 2, a catalyst for arachidonic acid metabolism not previously associated with VEGF signaling. The Orai3 drives endothelial cell 
remodeling and so these mechanisms may be important in cardiovascular and cancer disease processes.
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